May 12, 2020 / 4:12 PM / 20 days ago

BRIEF-Jubilant Life Sciences Limited Enters Into Licensing Agreement With Gilead For Remdesivir, A Potential Therapy For COVID-19

May 12 (Reuters) - Jubilant Life Sciences:

* JUBILANT LIFE SCIENCES LIMITED ENTERS INTO LICENSING AGREEMENT WITH GILEAD FOR REMDESIVIR, A POTENTIAL THERAPY FOR COVID-19

* JUBILANT LIFE - UNIT JUBILANT GENERICS ENTERED INTO A NON-EXCLUSIVE LICENSING AGREEMENT WITH GILEAD

* JUBILANT LIFE - AGREEMENT WILL GRANT JUBILANT RIGHT TO REGISTER, MANUFACTURE, SELL REMDESIVIR IN 127 COUNTRIES INCLUDING INDIA Source text: bit.ly/2yPRS0w Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below